We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
In an article by Glaucoma Physician, Jim Gallagher reports on the positive six-month results for VisiPlate® from the VITA trial presented by Dr. Eydie Miller-Ellis at the American Glaucoma Society (AGS). This was considered a top paper by the society and presented during the Surgery Day Paper Presentation at AGS. Dr. Miller-Ellis serves as the […]
Some medtech start-ups begin with an inventor with a novel idea; others seek out an unmet clinical need looking for a solution. Avisi Technologies began with market research, that is, a direct appeal to glaucoma specialists to determine what they were missing in their tool kits, and specifically, how the current generation of devices for minimally invasive […]
Summary of Avisi Involvement as Presenting Company 2024 and 2023 Panel Representation Avisi Technologies returned to the 2024 US Emerging Medtech Summit with updates about the development of VisiPlate, a nanotechnology-enabled aqueous shunt for the treatment of glaucoma. Avisi generated buzz in the Life Science Intelligence (LSI) community by announcing exclusive clinical data, showing promising […]
Interim trial results demonstrate the safety and effectiveness of VisiPlate® as a standalone treatment for primary open-angle glaucoma. REDWOOD CITY, Calif., (May 14, 2024) – Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant […]
Avisi Technologies has been shortlisted for Junkosha’s second-year Innovator of the Year Award program. This year had a tremendous number of applicants with Avisi Technologies being 1 of the 11 shortlisted to impress the panel of expert judges chosen for their vast industry experience in medical devices. The winning company will be awarded a $25,000 […]
Avisi, a trailblazing medical device company, is developing VisiPlate, a nanotechnology-enabled aqueous shunt designed to treat glaucoma. Working closely with ophthalmologists and experts, Avisi is committed to introducing a reliable, safe and effective solution for glaucoma patients.
